Advertisement

Picture Swiss Biotech Association LSE Global Village 2025 Basel 650x100px
Organisation › Details

BenevolentAI Ltd.

At BenevolentAI (AMS: BAI), we serve patients by leveraging our proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery. The Company’s business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, advancing in-house pipelines to inflection points, and commercialising a suite of knowledge exploration tools. Headquartered in London, with wet labs in Cambridge (UK) and an office in New York, BenevolentAI is at the forefront of reshaping the future of drug discovery and delivering innovative medicines. *

 

Period Start 2013-01-01 established
  Group BenevolentAI (Group)
Products Industry artificial intelligence (AI) / machine learning (ML)
  Industry 2 LIFE SCIENCES
Persons Person Möller, Jörg (BenevolentAI 202401– CEO before Leo Pharma + Bayer 201403–202012)
  Person 2 Isted, Catherine (BenevolentAI 202309– CFO before ReNeuron + Oxford Biomedica + Morgan Stanley + ABN AMRO + Nomura)
     
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 4–8 Maple Street
  City W1T 5HD London
  Tel +44-20-37819-360
    Address record changed: 2024-01-05
     
Basic data Employees D: 101 to 500 (2023-12-31)
  Currency GBP
  Annual sales 191,000 (operating income, other (2023) 2023-12-31)
  Profit -317,528,000 (2023-12-31)
  Cash 4,597,000 (2023-12-31)
     
    * Document for »About Section«: BenevolentAI Ltd.. (1/24/24). "Press Release: BenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer". London.
     
   
Record changed: 2024-10-19

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for BenevolentAI (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group BIO-Europe Spring 2025 Milan to 28 Feb 650x300px




» top